Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

SUMMIT THERAPEUTICS INC.

(SMMT)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-27 pm EST
3.230 USD   -7.71%
01/27Summit Therapeutics Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/26Akeso Receives First Tranche of Payment for Ivonescimab License Deal with Summit Therapeutics; Shares Climb 6%
MT
01/23Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific Antibody
AQ
SummaryQuotesChartsNewsCalendarCompanyFinancialsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Summit Therapeutics signs up to $5 bln licensing deal for experimental cancer therapy

12/06/2022 | 07:42am EST

Dec 6 (Reuters) - Summit Therapeutics Inc said on Tuesday it has signed a licensing deal worth up to $5 billion with China-based Akeso Inc for an experimental cancer therapy.

Summit said it would make an upfront payment of $500 million, and Akeso will be eligible for regulatory and commercial milestone payments of up to $4.5 billion. (Reporting by Leroy Leo in Bengaluru; Editing by Vinay Dwivedi)


ę Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
AKESO, INC. 0.99% 51 Delayed Quote.18.60%
SUMMIT THERAPEUTICS INC. -7.71% 3.23 Delayed Quote.-24.00%
All news about SUMMIT THERAPEUTICS INC.
01/27Summit Therapeutics Inc. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
01/26Akeso Receives First Tranche of Payment for Ivonescimab License Deal with Summit Therap..
MT
01/23Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative B..
AQ
01/20Summit Therapeutics Inc. : Entry into a Material Definitive Agreement, Change in Directors..
AQ
01/20Summit Therapeutics Inc. Appoints Yu Xia as Member of the Board
CI
01/20Summit Therapeutics Closes Deal With Akeso to Commercialize Lung Cancer Therapy
MT
01/20Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative B..
BU
01/09Transcript : Summit Therapeutics Inc. Presents at 41st Annual J.P. Morgan Hea..
CI
01/09Summit Therapeutics Inc. : Results of Operations and Financial Condition, Submission of Ma..
AQ
01/05Summit Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
BU
More news
Analyst Recommendations on SUMMIT THERAPEUTICS INC.
More recommendations
Financials
Sales 2021 1,81 M - -
Net income 2021 -88,6 M - -
Net cash 2021 69,0 M - -
P/E ratio 2021 -2,07x
Yield 2021 -
Capitalization 715 M 715 M -
EV / Sales 2020 373x
EV / Sales 2021 107x
Nbr of Employees 108
Free-Float 16,9%
Chart SUMMIT THERAPEUTICS INC.
Duration : Period :
Summit Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SUMMIT THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Managers and Directors
Robert William Duggan Executive Chairman & Chief Executive Officer
Mahkam Zanganeh President, Co-Chief Executive Officer & Director
Ankur Dhingra Chief Financial & Accounting Officer
Will Black Head-Information Technology
Danelle James Head-Clinical Development
Sector and Competitors
1st jan.Capi. (M$)
SUMMIT THERAPEUTICS INC.-24.00%715
VERTEX PHARMACEUTICALS11.16%82 513
REGENERON PHARMACEUTICALS, INC.2.88%79 336
WUXI APPTEC CO., LTD.20.37%42 407
BIONTECH SE-4.37%34 912
BEIGENE, LTD.18.12%27 008